Current Clinical Trials

Study of Personalized Cancer Therapy to Determine Response and Toxicity
  1. Henry Tsai, MD
    Henry Tsai, MD
  2. for people 7 Years and up (full criteria)
  3. Rancho Mirage, CA
  4. study started February 2017
  5. Henry Tsai, MD
  6. Accepting new patients

Description

Summary

The purpose of this study is to learn more about personalized cancer therapy including response to treatment and side effects. Information about the tests and treatments a person received, or will receive, for their cancer will be collected from medical records to help the researchers determine whether or not patients respond better when their physicians choose to treat them according to the genetic makeup of their tumor. Optional research tests may be performed on tissue, body cavity fluid, blood or urine provided, discarded biological samples taken during routine care that would normally be disposed of and not saved, or on blood samples collected for this study. These research tests will be used to create a "profile" of the collected specimens which will describe unique characteristics about the genes involved in a person's cancer. The tests will also help researchers look for biomarkers that may help predict how people respond to treatment.

Official Title

UCSD PREDICT - Profile Related Evidence Determining Individualized Cancer Therapy aka Study of Personalized Cancer Therapy to Determine Response and Toxicity

Detailed Description

This is a correlative study of personalized medicine with retrospective and prospective components. Patient medical records will be examined for results of molecular profiling obtained through standard of care testing to help understand, in a descriptive fashion, how well molecular testing might predict response to therapy. Patient outcome parameters including, but not limited to, tumor response, time to treatment failure, patient survival, and toxicity will be analyzed, as well as pharmacodynam... more
less

This is a correlative study of personalized medicine with retrospective and prospective components. Patient medical records will be examined for results of molecular profiling obtained through standard of care testing to help understand, in a descriptive fashion, how well molecular testing might predict response to therapy. Patient outcome parameters including, but not limited to, tumor response, time to treatment failure, patient survival, and toxicity will be analyzed, as well as pharmacodynamic (PD) and pharmacokinetic (PK) data when available. This study will also include optional research-related testing of tissue, blood, or urine specimens via a variety of simple or advanced techniques such as molecular, proteomic, and metabolic analyses for biomarker discovery or for PK and PD parameters. These specimens will be obtained from clinical specimens archived by UCSD Health System Pathology or from specimens collected via an existing IRB-approved protocol, discarded specimens, or from specimens collected for this protocol.

Keywords

Cancer

Eligibility

for people 7 Years and up
Inclusion Criteria: Must be willing to provide informed consent, parent permission, or assent Exclusion Criteria: Subjects unable to give informed consent, parent permission, or assent ... more
less

Inclusion Criteria: Must be willing to provide informed consent, parent permission, or assent Exclusion Criteria: Subjects unable to give informed consent, parent permission, or assent

Lead Scientists at Eisenhower Health

Henry Tsai, MD
For Henry Tung-Yun Tsai, MD, MA, a Board Certified Hematologist and Medical Oncologist – specializing in the treatment colon cancer and other gastrointestinal cancers, medicine has always been a part of his life. Originally from Taiwan, Dr. Tsai’s father and sisters all have careers in medicine – ranging in specialties from pharmacy to general surgery.  After having moved from Taiwan at age 14, Dr. Tsai attended the University of Calif... more
less

For Henry Tung-Yun Tsai, MD, MA, a Board Certified Hematologist and Medical Oncologist – specializing in the treatment colon cancer and other gastrointestinal cancers, medicine has always been a part of his life. Originally from Taiwan, Dr. Tsai’s father and sisters all have careers in medicine – ranging in specialties from pharmacy to general surgery. 

After having moved from Taiwan at age 14, Dr. Tsai attended the University of California at Berkeley where he received his Bachelor of Arts in molecular and cell biology/neurobiology. He received a Master of Arts degree in medical sciences from Boston University and attended medical school at Wayne State University School of Medicine in Detroit, Michigan.

Upon graduating from medical school, he moved to Atlanta, Georgia for an internship, residency and a fellowship in Hematology/Oncology at Emory University. It was at Emory where Dr. Tsai grew to love his chosen specialty: cancer care.

“Yes, cancer care is one of the most difficult fields to practice,” says Dr. Tsai. “But, it is also the most stimulating and rewarding. There are days when I see my patients get better and I have experienced hope. I feel privileged to be a part of their process.”

Dr. Tsai has been a member of the American Medical Association, American College of Physicians, American Society of Clinical Oncology. He has been the local principle investigator for various clinical trials and has presented at workshops and symposiums across the United States. He has authored a book chapter and manuscript related to cancer.

Clinical Study Details

  1. Accepting new patients
  2. study started February 2017
  3. Observational
  4. January 10, 2024